312 related articles for article (PubMed ID: 31324754)
1. Inhibition of the BET family reduces its new target gene IDO1 expression and the production of L-kynurenine.
Tian CQ; Chen L; Chen HD; Huan XJ; Hu JP; Shen JK; Xiong B; Wang YQ; Miao ZH
Cell Death Dis; 2019 Jul; 10(8):557. PubMed ID: 31324754
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells.
Iachininoto MG; Nuzzolo ER; Bonanno G; Mariotti A; Procoli A; Locatelli F; De Cristofaro R; Rutella S
Molecules; 2013 Aug; 18(9):10132-45. PubMed ID: 23973990
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.
Sartor GC; Powell SK; Brothers SP; Wahlestedt C
J Neurosci; 2015 Nov; 35(45):15062-72. PubMed ID: 26558777
[TBL] [Abstract][Full Text] [Related]
5. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
6. Effects of upregulated indoleamine 2, 3-dioxygenase 1 by interferon γ gene transfer on interferon γ-mediated antitumor activity.
Watcharanurak K; Zang L; Nishikawa M; Yoshinaga K; Yamamoto Y; Takahashi Y; Ando M; Saito K; Watanabe Y; Takakura Y
Gene Ther; 2014 Sep; 21(9):794-801. PubMed ID: 24919418
[TBL] [Abstract][Full Text] [Related]
7. Interferon-γ induces a tryptophan-selective amino acid transporter in human colonic epithelial cells and mouse dendritic cells.
Bhutia YD; Babu E; Ganapathy V
Biochim Biophys Acta; 2015 Feb; 1848(2):453-62. PubMed ID: 25450809
[TBL] [Abstract][Full Text] [Related]
8. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
[TBL] [Abstract][Full Text] [Related]
9. Regulation of inflammatory genes in decidual cells: Involvement of the bromodomain and extra-terminal family proteins.
Ajgaonkar S; Hirst JJ; Norris M; Zakar T
PLoS One; 2023; 18(3):e0280645. PubMed ID: 36897880
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer.
Lee J; Mashima T; Kawata N; Yamamoto N; Morino S; Inaba S; Nakamura A; Kumagai K; Wakatsuki T; Takeuchi K; Yamaguchi K; Seimiya H
Cancer Res Commun; 2024 May; 4(5):1307-1320. PubMed ID: 38669046
[TBL] [Abstract][Full Text] [Related]
11. BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis.
Roberts TC; Etxaniz U; Dall'Agnese A; Wu SY; Chiang CM; Brennan PE; Wood MJA; Puri PL
Sci Rep; 2017 Jul; 7(1):6153. PubMed ID: 28733670
[TBL] [Abstract][Full Text] [Related]
12. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
[TBL] [Abstract][Full Text] [Related]
13. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Coudé MM; Braun T; Berrou J; Dupont M; Bertrand S; Masse A; Raffoux E; Itzykson R; Delord M; Riveiro ME; Herait P; Baruchel A; Dombret H; Gardin C
Oncotarget; 2015 Jul; 6(19):17698-712. PubMed ID: 25989842
[TBL] [Abstract][Full Text] [Related]
14. In vitro cytokine licensing induces persistent permissive chromatin at the Indoleamine 2,3-dioxygenase promoter.
Rovira Gonzalez YI; Lynch PJ; Thompson EE; Stultz BG; Hursh DA
Cytotherapy; 2016 Sep; 18(9):1114-28. PubMed ID: 27421739
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Liu X; Shin N; Koblish HK; Yang G; Wang Q; Wang K; Leffet L; Hansbury MJ; Thomas B; Rupar M; Waeltz P; Bowman KJ; Polam P; Sparks RB; Yue EW; Li Y; Wynn R; Fridman JS; Burn TC; Combs AP; Newton RC; Scherle PA
Blood; 2010 Apr; 115(17):3520-30. PubMed ID: 20197554
[TBL] [Abstract][Full Text] [Related]
17. Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.
Volarevic V; Markovic BS; Jankovic MG; Djokovic B; Jovicic N; Harrell CR; Fellabaum C; Djonov V; Arsenijevic N; Lukic ML
Theranostics; 2019; 9(20):5976-6001. PubMed ID: 31534532
[TBL] [Abstract][Full Text] [Related]
18. Indoleamine 2,3-Dioxygenase Activity in
Virok DP; Raffai T; Kókai D; Paróczai D; Bogdanov A; Veres G; Vécsei L; Poliska S; Tiszlavicz L; Somogyvári F; Endrész V; Burián K
Front Cell Infect Microbiol; 2019; 9():192. PubMed ID: 31249813
[No Abstract] [Full Text] [Related]
19. Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma.
Shao J; Hou L; Liu J; Liu Y; Ning J; Zhao Q; Zhang Y
Front Immunol; 2021; 12():661357. PubMed ID: 33828565
[TBL] [Abstract][Full Text] [Related]
20. Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer.
Chen B; Alvarado DM; Iticovici M; Kau NS; Park H; Parikh PJ; Thotala D; Ciorba MA
Cancer Immunol Res; 2020 Apr; 8(4):451-464. PubMed ID: 32127391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
